Clindamycin HCl

Licensed by Pfizer Catalog No.S2457

For research use only.

Clindamycin HCl inhibits protein synthesis by acting on the 50S ribosomal, used for the treatment of bacterial infections.

Clindamycin HCl  Chemical Structure

CAS No. 21462-39-5

Selleck's Clindamycin HCl has been cited by 1 Publication

Purity & Quality Control

Choose Selective Bacterial Inhibitors

Biological Activity

Description Clindamycin HCl inhibits protein synthesis by acting on the 50S ribosomal, used for the treatment of bacterial infections.
Targets
50S ribosomal [1]
In vitro

Clindamycin is a classical inhibitor of bacterial protein synthesis, by binding to the 23S ribosomal RNA of the 50S ribosomal subunit. [1]

In vivo Clindamycin hydrochloride results in fast absorption after oral administration in dogs, with a mean absorption time (MAT) of 0.87 hour, and bioavailability is 72.55%. Clindamycin hydrochloride results in total clearance (CL) of Clindamycin after both IV and oral administration (0.503 vs. 0.458 L/h/kg) in dogs. Clindamycin hydrochloride results in volume of distribution at steady-state (IV) at 2.48 L/kg, indicating a wide distribution of clindamycin in body fluids and tissues. Clindamycin serum concentrations after IV and oral administration remain above 0.5 μg/mL approximately for 10 hours. [1] Clindamycin hydrochloride significantly reduces oral malodor from the dogs' baseline levels through 42 days. Clindamycin hydrochloride also results in significant reductions in dental plaque, dental calculus, and gingival bleeding in dogs. [2] Clindamycin hydrochloride (2.5 mg/lb), after ultrasonic scaling, root planing, and polishing (USRP) , has a significant effect on plaque and pocket depth measures of periodontal disease but not on gingivitis in canine. [3] Clindamycin hydrochloride results in complete remission ratio of 71.4% (15/21) in dogs with canine superficial bacterial pyoderma after treat within 14 to 28 days. [4]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 461.44
Formula

C18H33ClN2O5S.HCl

CAS No. 21462-39-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05223400 Not yet recruiting Drug: Clindamycin Injection Infection Bacterial Alexandria University March 2022 --
NCT04946500 Active not recruiting -- Prosthetic Joint Infection|Staphylococcus University Hospital Brest May 15 2021 --
NCT04220918 Recruiting -- Medication Adherence|Medication Reaction Children''s Hospital of Philadelphia|National Institute on Deafness and Other Communication Disorders (NIDCD)|Monell Chemical Senses Center February 14 2020 --
NCT03845790 Recruiting Other: Blood and microdialysis samples Surgical Site Infection Poitiers University Hospital May 26 2019 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Clindamycin HCl | Clindamycin HCl ic50 | Clindamycin HCl price | Clindamycin HCl cost | Clindamycin HCl solubility dmso | Clindamycin HCl purchase | Clindamycin HCl manufacturer | Clindamycin HCl research buy | Clindamycin HCl order | Clindamycin HCl mouse | Clindamycin HCl chemical structure | Clindamycin HCl mw | Clindamycin HCl molecular weight | Clindamycin HCl datasheet | Clindamycin HCl supplier | Clindamycin HCl in vitro | Clindamycin HCl cell line | Clindamycin HCl concentration | Clindamycin HCl nmr